1/2
08:00 am
sls
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
Medium
Report
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
12/10
08:42 am
sls
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia [Yahoo! Finance]
Medium
Report
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia [Yahoo! Finance]
12/10
08:30 am
sls
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Medium
Report
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
12/9
08:50 am
sls
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML [Yahoo! Finance]
Medium
Report
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML [Yahoo! Finance]
12/9
08:45 am
sls
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Medium
Report
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
11/27
08:45 am
sls
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
Medium
Report
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
11/13
06:05 pm
sls
SELLAS Life Sciences GAAP EPS of -$0.10 beats by $0.03 [Seeking Alpha]
Low
Report
SELLAS Life Sciences GAAP EPS of -$0.10 beats by $0.03 [Seeking Alpha]
11/13
04:15 pm
sls
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/5
09:55 am
sls
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
Low
Report
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
10/15
08:58 am
sls
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia [Yahoo! Finance]
Medium
Report
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia [Yahoo! Finance]
10/15
08:45 am
sls
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
Medium
Report
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
10/10
04:05 pm
sls
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Medium
Report
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit